Robbins Umeda LLP Announces An Investigation Of The Acquisition Of Ev3 Inc. By Covidien Plc

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of ev3 Inc. ("ev3" or the "Company") (NASDAQ: EVVV) in connection with their actions in causing ev3 to enter into a definitive merger agreement to be acquired by Covidien plc ("Covidien") (NYSE: COV). If the transaction is completed, ev3 shareholders will receive $22.50 in cash for each share of ev3 common stock they hold. The transaction, which will take the form of an all-cash tender offer by a wholly-owned subsidiary of Covidien followed by a second-step merger, is expected to be completed by July 31, 2010.

Robbins Umeda LLP's investigation concerns whether the Board of Directors of ev3 undertook a fair process to obtain fair consideration for all shareholders of ev3. Of particular note is that the Company had recently been upgraded to "market outperform" by BMO Capital Markets.

If you are a shareholder of ev3 and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at [e-mail].

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to http://www.robbinsumeda.com.

Advertisement

>To order reprints of this article, click here: Reprints